Unnamed: 0,title,date,stock,sentiment
61633.0,Alkermes To Highlight New Data From Schizophrenia Portfolio At The American Society Of Clinical Psychopharmacology 2020 Annual Meeting,2020-05-27 07:10:00-04:00,ALKS,positive
61634.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as optimism around a coronavirus vaccine increased following news from Moderna.,2020-05-18 10:23:00-04:00,ALKS,positive
61635.0,Alkermes To Present New Data From Schizophrenia Portfolio At SIRS Meeting,2020-05-14 07:15:00-04:00,ALKS,neutral
61636.0,Alkermes Announces 'Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA and VIVITROL',2020-05-11 07:14:00-04:00,ALKS,positive
61637.0,"HC Wainwright & Co. Reiterates Neutral on Alkermes, Lowers Price Target to $23",2020-04-30 07:23:00-04:00,ALKS,negative
61638.0,108 Biggest Movers From Yesterday,2020-04-30 05:30:00-04:00,ALKS,neutral
61639.0,Alkermes PLC shares are trading lower after the company reported Q1 earnings results.,2020-04-29 13:32:00-04:00,ALKS,neutral
61640.0,"Alkermes Q1 EPS $0.010 Beats $(0.060) Estimate, Sales $246.220M Beat $228.230M Estimate",2020-04-29 13:31:00-04:00,ALKS,neutral
61641.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,ALKS,positive
61642.0,Alkermes: Q1 Earnings Insights,2020-04-29 07:47:00-04:00,ALKS,neutral
61643.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,ALKS,negative
61644.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-04-23 07:31:00-04:00,ALKS,neutral
61645.0,Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.,2020-04-17 10:04:00-04:00,ALKS,positive
61646.0,Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.,2020-04-08 09:34:00-04:00,ALKS,positive
61647.0,"Morgan Stanley Maintains Equal-Weight on Alkermes, Lowers Price Target to $16",2020-04-02 09:03:00-04:00,ALKS,negative
61648.0,"B of A Securities Maintains Neutral on Alkermes, Lowers Price Target to $17",2020-03-23 08:46:00-04:00,ALKS,positive
61649.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,ALKS,positive
61650.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,ALKS,negative
61651.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,ALKS,negative
61652.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,ALKS,negative
61653.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,ALKS,positive
61654.0,Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia,2020-03-04 07:02:00-05:00,ALKS,neutral
61655.0,Shares of several healthcare and biotech companies are trading higher. Not seeing any news to justify the price action.,2020-02-26 14:28:00-05:00,ALKS,positive
61656.0,Shares of several healthcare and biotech companies are trading higher. Movement appears market related as equities have rebounded this session following recent selloffs.,2020-02-26 11:19:00-05:00,ALKS,positive
61657.0,Alkermes shares are trading higher. Not seeing any news to justify the price action.,2020-02-20 11:42:00-05:00,ALKS,positive
61658.0,Stocks That Hit 52-Week Lows On Friday,2020-02-14 10:29:00-05:00,ALKS,negative
61659.0,Alkermes PLC shares are trading lower after the company issued FY20 EPS and sales guidance on the lower end of analyst estimates.,2020-02-14 09:40:00-05:00,ALKS,negative
61660.0,"H.C. Wainwright Maintains Neutral on Alkermes, Lowers Price Target to $25",2020-02-14 09:30:00-05:00,ALKS,negative
61661.0,"JP Morgan Downgrades Alkermes to Neutral, Lowers Price Target to $21",2020-02-14 05:48:00-05:00,ALKS,positive
61662.0,Alkermes PLC shares are trading lower after the company issued FY20 EPS and sales guidance on the lower end of analyst estimates.,2020-02-13 11:37:00-05:00,ALKS,negative
61663.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,ALKS,negative
61664.0,Alkermes Sees FY20 Sales $1.03B-$1.08B vs $1.06B Estimate,2020-02-13 07:19:00-05:00,ALKS,neutral
61665.0,Alkermes Sees FY20 Adj. EPS $0.25-$0.44 vs $0.44 Estimate,2020-02-13 07:18:00-05:00,ALKS,neutral
61666.0,"Alkermes Q4 EPS $0.83 Beats $0.65 Estimate, Sales $412.7M Beat $404.5M Estimate",2020-02-13 07:16:00-05:00,ALKS,neutral
61667.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,ALKS,neutral
61668.0,"Mizuho Initiates Coverage On Alkermes with Neutral Rating, Announces $19 Price Target",2020-02-06 05:20:00-05:00,ALKS,neutral
61669.0,"Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings",2020-02-05 16:42:00-05:00,ALKS,neutral
61670.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,ALKS,positive
61671.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,ALKS,negative
61672.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,ALKS,positive
61673.0,Alkermes Announces FDA Acceptance Of ALKS 3831 New Drug Application For Treatment Of Schizophrenia And Bipolar I Disorder,2020-01-28 07:04:00-05:00,ALKS,positive
61674.0,Alkermes Option Alert: Feb 21 $18 Puts at the Bid: 2607 @ $0.5 vs 13 OI; Earnings 2/13 Before Open [est] Ref=$19.465,2020-01-17 13:45:00-05:00,ALKS,positive
61675.0,"UPDATE: FDA Says Alkermes' Vivitrol Ad Use Is False/Misleading, Omits Important Risk Info",2019-12-11 11:00:00-05:00,ALKS,negative
61676.0,FDA's Office Of Prescription Drug Promotion Reviewed Print Ad By Alkermes For Vivitrol,2019-12-11 10:58:00-05:00,ALKS,neutral
61677.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,ALKS,negative
61678.0,Alkermes Submits New Drug Application To FDA For ALKS 3831 For Treatment Of Schizophrenia And Bipolar I Disorder,2019-11-19 07:00:00-05:00,ALKS,negative
61679.0,Alkermes PLC shares are trading lower after the company announced it would acquire Rodin Therapeutics for $100 million in cash.,2019-11-18 10:49:00-05:00,ALKS,neutral
61680.0,Alkermes to Acquires Rodin Therapeutics for $100M Cash,2019-11-18 07:02:00-05:00,ALKS,neutral
61681.0,Alkermes Receives $150M Milestone Payment From Biogen Related To FDA Approval Of VUMERITY,2019-11-12 07:17:00-05:00,ALKS,positive
61682.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,ALKS,neutral
61683.0,Biotech Stock On The Radar: Alkermes At A Crossroads,2019-11-07 11:53:00-05:00,ALKS,neutral
61684.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,ALKS,neutral
61685.0,Biogen And Alkermes Announce FDA Approval Of VUMERITY (diroximel fumarate) For Multiple Sclerosis,2019-10-30 07:30:00-04:00,ALKS,positive
61686.0,Alkermes shares are trading higher on continued strength after the company on Wednesday reported strong Q3 results.,2019-10-24 11:42:00-04:00,ALKS,positive
61687.0,Alkermes PLC shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-10-23 09:15:00-04:00,ALKS,positive
61688.0,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-23 08:48:00-04:00,ALKS,neutral
61689.0,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",2019-10-23 07:54:00-04:00,ALKS,negative
61690.0,Alkermes Sees $150M In Cost Savings From Restructuring,2019-10-23 07:06:00-04:00,ALKS,neutral
61691.0,"Alkermes Sees FY19Adj. EPS $0.44-$0.57, Sakes $1.14B-$1.19B",2019-10-23 07:05:00-04:00,ALKS,neutral
61692.0,"Alkermes Q3 Adj. EPS $(0.04) Beats $(0.21) Estimate, Sales $255.2M Beat $251.16M Estimate",2019-10-23 07:04:00-04:00,ALKS,neutral
61693.0,Alkermes to Collaborate with Fred Hutchinson Cancer Research Center on Immuno-Oncology Drug Candidate ALKS 4230,2019-10-21 07:04:00-04:00,ALKS,negative
61694.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,ALKS,positive
61695.0,Alkermes shares are trading lower despite no company-specific news. The stock has dropped approximately 26% over the last month.,2019-10-10 13:44:00-04:00,ALKS,positive
61696.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-08 12:02:00-04:00,ALKS,negative
61697.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,ALKS,negative
61698.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,ALKS,positive
61699.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,ALKS,negative
61700.0,"Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.",2019-10-01 13:02:00-04:00,ALKS,negative
61701.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,ALKS,negative
61702.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,ALKS,negative
61703.0,"Alkermes shares are trading lower after the stock could not stay above the $21 support level. NOTE: An overnight filing showed that the company's CEO exercised an option for 100,000 shares and sold at $21.5355 per share as part of his compensation. This does not normally cause the stock to trade lower.",2019-09-24 12:45:00-04:00,ALKS,positive
61704.0,Alkermes shares trading lower as stock pulls back from $23 resistance level. The stock rallied 12% over Tuesday and Wednesday of last week to push over the $21 level. Did not see news to justify the recent moves.,2019-09-17 11:08:00-04:00,ALKS,neutral
61705.0,UPDATE: Morgan Stanley On Alkermes Also Notes 'We see long-term risk to royalty streams balanced by pipeline or cost savings optionality',2019-09-05 11:07:00-04:00,ALKS,negative
61706.0,"UPDATE: Morgan Stanley Upgrades Alkermes To Equal-Weight, Lowers Target To $20 As Firm Notes 'Shares have underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent'",2019-09-05 11:07:00-04:00,ALKS,positive
61707.0,"Benzinga's Top Upgrades, Downgrades For September 5, 2019",2019-09-05 09:38:00-04:00,ALKS,positive
61708.0,"Morgan Stanley Upgrades Alkermes to Equal-Weight, Lowers Price Target from $30 to $20",2019-09-05 07:05:00-04:00,ALKS,negative
61709.0,Stocks That Hit 52-Week Lows On Monday,2019-08-26 10:28:00-04:00,ALKS,negative
61710.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,ALKS,positive
61711.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,ALKS,negative
61712.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,ALKS,positive
61713.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,ALKS,neutral
61714.0,Alkermes PLC shares are trading higher after the company reported that the Diroximel Fumarate demonstrated statistically Superior Gastrointestinal Tolerability for the company's EVOLVE-MS-2 primary endpoint.,2019-07-30 14:58:00-04:00,ALKS,positive
61715.0,"Alkermes, Biogen Report Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events",2019-07-30 07:36:00-04:00,ALKS,positive
61716.0,"Alkermes Enters Into A Settlement And License Agreement  With Amneal Pharmaceuticals To Resolve Amneal's Inter Partes Review Petition Challenging U.S. Patent Number 7,919,499, For Vivitrol That Expires In 2029",2019-07-29 12:33:00-04:00,ALKS,positive
61717.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,ALKS,negative
61718.0,Stocks That Managed to Breach 52-Week Lows Friday,2019-07-26 15:45:00-04:00,ALKS,negative
61719.0,"The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint",2019-07-26 07:26:00-04:00,ALKS,neutral
61720.0,Alkermes shares are trading lower after the company reported Q2 earnings results.,2019-07-25 12:22:00-04:00,ALKS,neutral
61721.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,ALKS,negative
61722.0,"Alkermes Q2 EPS $0.09 Beats $(0.12) Estimate, Sales $279.872M Beat $251.39M Estimate",2019-07-25 07:14:00-04:00,ALKS,neutral
61723.0,"Benzinga's Top Upgrades, Downgrades For July 15, 2019",2019-07-15 09:38:00-04:00,ALKS,positive
61724.0,Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder,2019-07-15 07:02:00-04:00,ALKS,negative
61725.0,"Goldman Sachs Upgrades Alkermes to Neutral, Announces $27 Price Target",2019-07-15 06:28:00-04:00,ALKS,neutral
61726.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,ALKS,positive
61727.0,Alkermes Initiates Monotherapy Expansion Phase Of ARTISTRY-1 In Patients With Renal Cell Carcinoma Or Melanoma,2019-06-12 07:05:00-04:00,ALKS,neutral
61728.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,ALKS,positive
61729.0,"H.C. Wainwright Initiates Coverage On Alkermes with Neutral Rating, Announces $28 Price Target",2019-05-31 07:46:00-04:00,ALKS,neutral
61730.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,ALKS,positive
61731.0,"The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug",2019-05-30 07:33:00-04:00,ALKS,positive
61732.0,"The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation",2019-05-29 07:38:00-04:00,ALKS,neutral
61733.0,"The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice",2019-05-24 07:44:00-04:00,ALKS,neutral
61734.0,Alkermes Reports Will Present New Data From Mental Health Portfolio At American Society of Clinical Psychopharmacology 2019 Annual Meeting,2019-05-22 07:06:00-04:00,ALKS,neutral
61735.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,ALKS,negative
61736.0,"The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings",2019-05-14 07:42:00-04:00,ALKS,positive
61737.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,ALKS,negative
61738.0,10 Biggest Price Target Changes For Wednesday,2019-05-01 09:44:00-04:00,ALKS,neutral
61739.0,"Citigroup Downgrades Alkermes plc - Ordinary Shares to Neutral, Lowers Price Target to $33",2019-05-01 07:48:00-04:00,ALKS,positive
61740.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,ALKS,negative
61741.0,55 Biggest Movers From Yesterday,2019-04-26 04:49:00-04:00,ALKS,neutral
61742.0,Alkermes shares trading lower despite reporting better-than-expected Q1 results.,2019-04-25 09:41:00-04:00,ALKS,neutral
61743.0,"The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings",2019-04-25 07:58:00-04:00,ALKS,neutral
61744.0,"Alkermes Q1 Adj. EPS $(0.17) Beats $(0.22) Estimate, Sales $223.102M Beat $216.99M Estimate",2019-04-25 07:48:00-04:00,ALKS,neutral
61745.0,"The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug",2019-04-11 07:48:00-04:00,ALKS,positive
61746.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-04-09 07:59:00-04:00,ALKS,neutral
61747.0,Alkermes' ARISTADA Met its Primary Endpoint,2019-04-09 07:02:00-04:00,ALKS,neutral
61748.0,"Alkermes Reports Pres, COO Jim Robinson To Leave Co.",2019-04-08 17:15:00-04:00,ALKS,negative
61749.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-04-07 17:04:00-04:00,ALKS,neutral
61750.0,"Alkermes, Merck, Sage Therapeutics and Takeda Pharma Announce a Partnership to Qualify Biomarkers for Schizophrenia Drug Development",2019-04-01 07:07:00-04:00,ALKS,neutral
61751.0,Alkermes Reports Initiation Of Clinical Study Of ALKS 4230 Administered Subcutaneously In Patients With Advanced Solid Tumors,2019-02-26 07:07:00-05:00,ALKS,positive
61752.0,Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis,2019-02-25 07:37:00-05:00,ALKS,positive
61753.0,Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies,2019-02-19 07:01:00-05:00,ALKS,negative
61754.0,"The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial",2019-02-14 07:50:00-05:00,ALKS,negative
61755.0,Alkermes Sees FY19 Sales Of Proprietary Products Up ~24% Year Over Year,2019-02-14 07:05:00-05:00,ALKS,neutral
61756.0,"Alkermes Q4 EPS $0.34 Up From $0.31 YoY, Sales $315.8M Beat $255.09M Estimate",2019-02-14 07:05:00-05:00,ALKS,neutral
61757.0,Alkermes Receives Complete Response Letter From FDA For ALKS 5461 New Drug Application; FDA Said It Is Unable To Approve Drug In Its Current Form And Is Requesting Additional Clinical Data,2019-02-01 16:02:00-05:00,ALKS,neutral
61758.0,"The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug",2019-01-31 09:01:00-05:00,ALKS,negative
61759.0,"Allakos Announces Phase 2 Results Of AK002 In Patients With Cholinergic Urticaria And Symptomatic Dermographism; Results Show 82% Response Rate In Cholinergic Urticaria Patients, 70% In Symptomatic Dermographism Patients",2019-01-29 08:05:00-05:00,ALKS,neutral
61760.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-01-27 16:07:00-05:00,ALKS,neutral
61761.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2018-12-31 09:00:00-05:00,ALKS,neutral
61762.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,ALKS,negative
61763.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,ALKS,positive
61764.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,ALKS,negative
61765.0,UPDATE: Goldman Sachs Downgrades Alkermes As Recent Checks Show 'the current profile of ALKS-3831 for schizophrenia based on weight gain alone suggests that the drug is unlikely to be practice changing',2018-12-19 10:51:00-05:00,ALKS,positive
61766.0,10 Biggest Price Target Changes For Wednesday,2018-12-19 09:44:00-05:00,ALKS,neutral
61767.0,"Alkermes Catches A 'Sell' Downgrade On Depression Therapy, M&A Prospects",2018-12-19 09:29:00-05:00,ALKS,negative
61768.0,"Benzinga's Top Upgrades, Downgrades For December 19, 2018",2018-12-19 09:11:00-05:00,ALKS,positive
61769.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,ALKS,positive
61770.0,"Goldman Sachs Downgrades Alkermes to Sell, Lowers Price Target to $26",2018-12-19 06:43:00-05:00,ALKS,negative
61771.0,Alkermes Shares Indicated Down 5-6% After Hours On Light Volume; Hearing Goldman Issued Post-Market Downgrade To Sell,2018-12-18 16:30:00-05:00,ALKS,positive
61772.0,Alkermes And Biogen Announce Submission Of New Drug Application To U.S. Food And Drug Administration For Diroximel Fumarate In Multiple Sclerosis,2018-12-17 07:31:00-05:00,ALKS,neutral
61773.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-12-13 13:11:00-05:00,ALKS,neutral
61774.0,Alkermes shares are trading lower after Credit Suisse lowered its rating on the stock from outperform to underperform and lowered its price target from $47 to $31.,2018-12-13 10:33:00-05:00,ALKS,positive
61775.0,"Credit Suisse Downgrades Alkermes to Underperform, Lowers Price Target to $31",2018-12-13 08:38:00-05:00,ALKS,positive
61776.0,What's Going On With Adial Pharmaceuticals?,2018-11-30 14:03:00-05:00,ALKS,neutral
61777.0,Alkermes Shares Resume Trade,2018-11-29 07:31:00-05:00,ALKS,positive
61778.0,Alkermes Shares To Resume Trade At 7:30 a.m. EST,2018-11-29 07:05:00-05:00,ALKS,positive
61779.0,Alkermes Says Plans To Submit New Drug Application For ALKS 3831 In Mid 2019,2018-11-29 07:01:00-05:00,ALKS,neutral
61780.0,Alkermes Reports ALKS 3831 Trial Met Both Co-Primary Endpoints,2018-11-29 07:01:00-05:00,ALKS,neutral
61781.0,Alkermes Shares Halted News Pending,2018-11-29 06:56:00-05:00,ALKS,positive
61782.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018",2018-11-15 11:37:00-05:00,ALKS,negative
61783.0,"Leerink Swann Initiates Coverage On Alkermes with Market Perform Rating, Announces $36 Price Target",2018-11-15 09:16:00-05:00,ALKS,neutral
61784.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,ALKS,positive
61785.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,ALKS,neutral
61786.0,"Leerink Swann Initiates Coverage On Alkermes with Market Perform Rating, Announces $36 Price Target",2018-11-13 08:51:00-05:00,ALKS,neutral
61787.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,ALKS,negative
61788.0,Morgan Stanley On Alkermes: Reiterates Underweight As They Expect Disappointing Data On ALKS 3831,2018-11-12 10:19:00-05:00,ALKS,negative
61789.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,ALKS,neutral
61790.0,Alkermes To Present New Data On ALKS 4230 At Society For Immunotherapy Of Cancer's (SITC) 33rd Annual Meeting,2018-11-06 08:39:00-05:00,ALKS,neutral
61791.0,"Benzinga's Top Upgrades, Downgrades For November 5, 2018",2018-11-05 09:05:00-05:00,ALKS,positive
61792.0,"PiperJaffray Initiates Coverage On Alkermes with Neutral Rating, Announces $40 Price Target",2018-11-05 06:08:00-05:00,ALKS,neutral
61793.0,FDA Committees' Unfavorable Ruling Depresses Alkermes Shares,2018-11-02 10:16:00-04:00,ALKS,negative
61794.0,"The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug",2018-11-02 08:01:00-04:00,ALKS,negative
61795.0,Alkermes Says 'Disappointed and Surprised' by FDA Advisory Committee Negative Vote on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder,2018-11-02 04:05:00-04:00,ALKS,negative
61796.0,Alkermes Shares To Resume Trade At 6:45 p.m. EDT,2018-11-01 18:40:00-04:00,ALKS,positive
61797.0,'Ad comm votes 2-21 that the available data do NOT support a favorable benefit-risk profile of $ALKS' buprenorphine/samidorphan to support approval' -Tweet From Pharma Pink Sheet Reporter Michael Cipriano On Alkermes AdCom,2018-11-01 16:51:00-04:00,ALKS,negative
61798.0,"'Vote tally is Yes: 3, No: 20.' -CNBC's Meg Tirrell Tweets On Alkermes AdCom Panel Vote For ALKS 5461",2018-11-01 16:01:00-04:00,ALKS,positive
61799.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2018-11-01 09:26:00-04:00,ALKS,neutral
61800.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,ALKS,negative
61801.0,UPDATE: Alkermes Shares Halted Ahead of FDA Panel,2018-11-01 07:23:00-04:00,ALKS,positive
61802.0,Alkermes Shares Halted News Pending,2018-11-01 06:56:00-04:00,ALKS,positive
61803.0,REMINDER: Alkermes Has FDA AdCom Meting for ALKS 5461 Today; Despite Refusal to File Letter On 4/2/18 Co. Announced Its NDA Was Accepted 4/16/18,2018-11-01 05:59:00-04:00,ALKS,positive
61804.0,30 Stocks Moving In Tuesday's Pre-Market Session,2018-10-30 08:56:00-04:00,ALKS,neutral
61805.0,'FDA briefing documents for $ALKS '5461 panel are live' -Tweet From STAT News' Adam Feuerstein,2018-10-30 07:38:00-04:00,ALKS,neutral
61806.0,"Alkermes Issues Press Release Highlighting Publication Of Previously-Disclosed Phase 3 Data For ALKS 5461 For Adjunctive Treatment of Major Depressive Disorder; BZ NOTE: Advisory Committee Panel Meeting For ALKS 5461 Is Scheduled Thurs., Nov. 1, 2018",2018-10-29 13:15:00-04:00,ALKS,negative
61807.0,"Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?",2018-10-29 13:10:00-04:00,ALKS,positive
61808.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,ALKS,neutral
61809.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,ALKS,negative
61810.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,ALKS,negative
61811.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,ALKS,positive
61812.0,"UPDATE: Alkermes Raises FY18 Sales Guidance From $975M-$1.025B To $1.015B-$1.045B vs $1.02B Estimate, Sees Adj. EPS $0.12-$0.31 vs $0.07 Est.",2018-10-23 07:05:00-04:00,ALKS,neutral
61813.0,Alkermes Raises Guidance,2018-10-23 07:03:00-04:00,ALKS,neutral
61814.0,"Alkermes plc Q3 EPS $0.07 Beats $(0.07) Estimate, Sales $248.72M Beat $237.26M Estimate",2018-10-23 07:03:00-04:00,ALKS,neutral
61815.0,Alkermes Q3 Earnings Preview,2018-10-22 14:41:00-04:00,ALKS,neutral
61816.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,ALKS,neutral
61817.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,ALKS,negative
61818.0,"The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares",2018-09-18 08:44:00-04:00,ALKS,positive
61819.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,ALKS,negative
61820.0,Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab,2018-09-10 07:05:00-04:00,ALKS,positive
61821.0,"Oklahoma Healthcare Authority Says Medicaid Program Signs First 'Value-Based' Contract For Alkermes Antipsychotic Drug, Says Two Similar Prescription Deals Are In The Works",2018-08-24 09:47:00-04:00,ALKS,positive
61822.0,"Benzinga's Top Upgrades, Downgrades For August 7, 2018",2018-08-07 09:03:00-04:00,ALKS,positive
61823.0,"Stifel Nicolaus Initiates Coverage On Alkermes with Hold Rating, Announces $45 Price Target",2018-08-07 07:21:00-04:00,ALKS,neutral
61824.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,ALKS,negative
61825.0,Alkermes Reaffirms FY18 Outlook,2018-07-26 07:18:00-04:00,ALKS,neutral
61826.0,"Alkermes Q2 EPS $0.29 Beats $0.14 Estimate, Sales $304.642M Beat $247.08M Estimate",2018-07-26 07:17:00-04:00,ALKS,neutral
61827.0,Earnings Preview: Alkermes,2018-07-25 14:33:00-04:00,ALKS,neutral
61828.0,"UPDATE: Acorda, Alkermes v. Roxane Labs, Mylan, Teva Doc Shows 'On July 23, 2018, Acorda notified the court that ""Acorda plans to seek an emergency injunction on July 25, 2018 absent a change in circumstances.""'",2018-07-25 11:29:00-04:00,ALKS,negative
61829.0,"Hearing Acorda Loses Bid For Emergency Order Blocking Ampyra Copy, Co. Is Awaiting Decision On Validity Of Ampyra Patents",2018-07-25 11:19:00-04:00,ALKS,negative
61830.0,"UPDATE: Alkermes Veterans Affair Contract For 'Single source innovator, multiple source innovator, biological & insulin pharmaceutical products'",2018-07-16 11:40:00-04:00,ALKS,neutral
61831.0,"Alkermes Shares Spike To Session High Over $45, Up 1.7% For Session; Traders Circulate FedBizOpps.gov Alert Co. Awarded Dept. Of Veterans Affairs Contract For ~$186M",2018-07-16 11:35:00-04:00,ALKS,positive
61832.0,Analyst: Opioid Legislation Likely Stalled In Senate Until After November Elections,2018-07-14 13:54:00-04:00,ALKS,negative
61833.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,ALKS,neutral
61834.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-02 09:10:00-04:00,ALKS,neutral
61835.0,Alkermes' ARISTDAD INITIO is Approved by the FDA for the Initiation of ARISTADA for Schizophrenia,2018-07-02 07:02:00-04:00,ALKS,positive
61836.0,REMINDER: Alkermes Has PDUFA Date for ARISTADA June 30th,2018-06-29 14:05:00-04:00,ALKS,neutral
61837.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,ALKS,positive
61838.0,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",2018-06-28 08:26:00-04:00,ALKS,positive
61839.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs",2018-06-24 10:43:00-04:00,ALKS,neutral
61840.0,56 Biggest Movers From Yesterday,2018-06-22 04:08:00-04:00,ALKS,neutral
61841.0,Alkermes PLC Shares Down 13.3% After Morgan Stanley Earlier Downgraded Stock From Equal-Weight To Underweight And Lowered Price Target From $67 To $42,2018-06-21 14:00:00-04:00,ALKS,positive
61842.0,44 Stocks Moving In Thursday's Mid-Day Session,2018-06-21 13:50:00-04:00,ALKS,neutral
61843.0,"Benzinga's Top Upgrades, Downgrades For June 21, 2018",2018-06-21 08:57:00-04:00,ALKS,positive
61844.0,"Morgan Stanley Downgrades Alkermes to Underweight, Lowers Price Target to $42",2018-06-21 07:15:00-04:00,ALKS,negative
61845.0,"Benzinga's Top Upgrades, Downgrades For June 6, 2018",2018-06-06 09:16:00-04:00,ALKS,positive
61846.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-06 08:53:00-04:00,ALKS,neutral
61847.0,"B. Riley FBR Initiates Coverage On Alkermes with Buy Rating, Announces $60 Price Target",2018-06-06 07:07:00-04:00,ALKS,neutral
61848.0,UPDATE: Alkermes Says May Also Receive $150M Milestone Payment From Biogen Upon FDA Approval Of NDA For BIIB098,2018-06-06 07:04:00-04:00,ALKS,positive
61849.0,Alkermes Reports Received $50M Payment From Biogen Related To Review Of Prelim. Gastrointestinal Tolerability Data From Ongoing BIIB098 Development Program,2018-06-06 07:04:00-04:00,ALKS,neutral
61850.0,Citigroup Upgrades Alkermes to Buy,2018-05-16 07:55:00-04:00,ALKS,neutral
61851.0,"Bank of America Initiates Coverage On Alkermes with Buy Rating, Announces $56 Price Target",2018-05-11 09:12:00-04:00,ALKS,neutral
61852.0,"Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings",2018-04-26 08:07:00-04:00,ALKS,neutral
61853.0,"Alkermes Q1 Adj. EPS $(0.09) Misses $(0.07) Est., Sales $225.2M Beats $219M Est.",2018-04-26 07:07:00-04:00,ALKS,negative
61854.0,38 Biggest Movers From Yesterday,2018-04-17 04:46:00-04:00,ALKS,neutral
61855.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-16 12:19:00-04:00,ALKS,neutral
61856.0,Mid-Day Market Update: Crude Oil Down Over 1%; Eldorado Resorts Shares Surge,2018-04-16 12:02:00-04:00,ALKS,negative
61857.0,Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Estimates,2018-04-16 10:42:00-04:00,ALKS,positive
61858.0,23 Stocks Moving In Monday's Pre-Market Session,2018-04-16 08:10:00-04:00,ALKS,neutral
61859.0,Alkermes Reports FDA Acceptance For Review NDA For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder,2018-04-16 06:50:00-04:00,ALKS,negative
61860.0,41 Biggest Movers From Yesterday,2018-04-03 04:18:00-04:00,ALKS,neutral
61861.0,Mid-Afternoon Market Update: Dow Falls Over 500 Points; Crude Oil Down 2.5%,2018-04-02 14:34:00-04:00,ALKS,negative
61862.0,33 Stocks Moving In Monday's Mid-Day Session,2018-04-02 12:53:00-04:00,ALKS,neutral
61863.0,"'Talking $ALKS FDA decision and implications for other biotechs, coming up on @HalftimeReport'",2018-04-02 12:28:00-04:00,ALKS,neutral
61864.0,Mid-Day Market Update: NASDAQ Down Over 2%; SELLAS Life Sciences Shares Spike Higher,2018-04-02 12:05:00-04:00,ALKS,positive
61865.0,Alkermes Shares Fall To Session Lows; Hearing Evercore ISI Issued Mid-Day Downgrade On Issue,2018-04-02 11:52:00-04:00,ALKS,positive
61866.0,"Benzinga Pro's Most-Searched Tickers For Mon., Apr. 2, 2018",2018-04-02 11:40:00-04:00,ALKS,neutral
61867.0,Mid-Morning Market Update: Markets Open Lower; Cal-Maine Foods Posts Upbeat Sales,2018-04-02 10:20:00-04:00,ALKS,negative
61868.0,"Alkermes CEO, Asked About FDA's Decision On Co.'s Depression Drug On Conf. Call, Says 'We don't believe any additional clinical trials are necessary'",2018-04-02 08:57:00-04:00,ALKS,negative
61869.0,Alkermes Falls 20% After FDA Refusal To File Letter,2018-04-02 08:38:00-04:00,ALKS,neutral
61870.0,28 Stocks Moving In Monday's Pre-Market Session,2018-04-02 08:00:00-04:00,ALKS,neutral
61871.0,"Alkermes Receives Refusal to File Letter From FDA for ALKS 5461, Alkermes to Provide Updated Guidance",2018-04-02 07:10:00-04:00,ALKS,neutral
61872.0,"Adam F Tweet: $ALKS — '5461 RTF letter is a big setback. Richard Pops assured investors this drug was getting approved, despite all the conflicting clinical data.",2018-04-02 07:04:00-04:00,ALKS,positive
61873.0,"Alkermes Halted, News Pending",2018-04-02 06:58:00-04:00,ALKS,neutral
61874.0,Alkermes Appoints James Robinson as President and COO,2018-03-01 07:01:00-05:00,ALKS,neutral
61875.0,"Benzinga's Top Upgrades, Downgrades For February 22, 2018",2018-02-22 09:57:00-05:00,ALKS,positive
61876.0,"The Market In 5 Minutes: Jobless Claims Fall, 10-Year Treasury Yields, Twitter Makes Some Changes",2018-02-22 09:04:00-05:00,ALKS,positive
61877.0,Jefferies Downgrades Alkermes to Hold,2018-02-22 06:32:00-05:00,ALKS,neutral
61878.0,"Alkermes Sees FY18 Sales $975-$1.025B vs $999M Est., EPS $(0.23)-$(0.03)",2018-02-14 07:12:00-05:00,ALKS,neutral
61879.0,"Alkermes Reports Q4 EPS $0.33 vs $0.23 Est., Sales $275M vs $252M Est.",2018-02-14 07:11:00-05:00,ALKS,neutral
61880.0,"Shares of Alkermes Trade Higher Following Chatter That Nektar Therapeutics Has Takeover Interest from Larger Drug Makers, Alkermes' Products Have Similarities to Nektar",2018-02-02 15:30:00-05:00,ALKS,positive
61881.0,Alkermes Reports Submission Of NDA For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder,2018-01-31 14:02:00-05:00,ALKS,negative
61882.0,"JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics",2018-01-09 09:02:00-05:00,ALKS,positive
61883.0,PRIMECAP Management Reports 11.35% Stake In Alkermes,2017-12-05 12:06:00-05:00,ALKS,neutral
61884.0,Senior S&P Global News Reporter Donna Young Tweets '.@andrewkolodny says he has serious concerns about $ALKS Vivitrol being used in wrong patients. We don't have good data on best med for right patient...',2017-11-30 11:35:00-05:00,ALKS,negative
61885.0,Alkermes Wins '061 Patent Trial Over Lyue Pharma As Multi-Drug Patent Claims Upheld As Valid,2017-11-28 13:33:00-05:00,ALKS,positive
61886.0,"Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis, Plans to Submit NDA in 2018",2017-11-27 07:04:00-05:00,ALKS,positive
61887.0,"UPDATE: Alkermes Highlights FDA Action For Aripiprazole Lauroxil NanoCrystal® Dispersion Jun. 30, 2018",2017-11-16 07:08:00-05:00,ALKS,neutral
61888.0,Alkermes Reports NDA For 'Initiation With Aripiprazole Lauroxil NanoCrystal Dispersion® Designed to Replace Need for Concomitant Three Weeks of Oral Aripiprazole With First ARISTADA Dose',2017-11-16 07:07:00-05:00,ALKS,neutral
61889.0,"Alkermes Tues. Afternoon Highlighted VIVITROL, Value Of Medication-Assisted Treatment Of Opioid Dependence Featured In Study Sponsored By National Institute On Drug Abuse",2017-11-15 09:12:00-05:00,ALKS,negative
61890.0,"Jefferies 2107 London Healthcare Conference Begins Today, Presenters Include: Alkermes, Bristol-Myers, Immunogen, and Eagle Pharmaceuticals",2017-11-15 09:00:00-05:00,ALKS,neutral
61891.0,Alkermes Reports Preclinical Data For ALKS 4230 Showed 'Preferential Expansion and Tumor Infiltration of Select Tumor-Killing Immune Cells in Preclinical Xenograft Model of Metastatic Melanoma',2017-11-08 07:03:00-05:00,ALKS,negative
61892.0,Adam Feuerstein Tweets: I get why Kamala Harris piling on $ALKS for Vivitrol marketing is newsworthy but it's also nonsensical political grandstanding at its worst.,2017-11-06 15:17:00-05:00,ALKS,negative
61893.0,Senator Harris Releases Statement Launching Investigation Into Alkermes Regarding Opioid Addiction Treatment Manipulation,2017-11-06 11:15:00-05:00,ALKS,negative
61894.0,Alkermes Shares Plunge To Sesion Lows As Traders Circulate Word Senator Harris Has Launched Probe Into Co.'s Vivitrol,2017-11-06 10:30:00-05:00,ALKS,positive
61895.0,Alkermes Sees FY17 Adj. EPS $(0.10)-$0.10 vs $(0.04) Est.,2017-10-26 07:20:00-04:00,ALKS,neutral
61896.0,"Alkermes Reports Q3 Adj. EPS $0.03 vs $(0.01) Est., Sales $217.4M vs $231M Est.",2017-10-26 07:18:00-04:00,ALKS,neutral
61897.0,Alkermes Publishes PR Titled New Study Comparing Effectiveness of Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry,2017-10-18 11:16:00-04:00,ALKS,neutral
61898.0,"Stat News Reporter Rebecca Robbins Tweets: Big study news: Compared head to head, Vivitrol works as well as Suboxone for short-term abstinence from heroin.",2017-10-18 11:08:00-04:00,ALKS,negative
61899.0,Barclays Downgrades Alkermes plc - Ordinary Shares to Equal-Weight,2017-10-16 06:26:00-04:00,ALKS,positive
61900.0,Alkermes Gives Update on ARISTADA,2017-09-18 07:14:00-04:00,ALKS,neutral
61901.0,Watch These 8 Huge Call Purchases In Friday Trade,2017-09-08 04:03:00-04:00,ALKS,positive
61902.0,Benzinga's Option Alert Recap From September 7,2017-09-07 16:37:00-04:00,ALKS,positive
61903.0,Alkermes Option Alert: Sep 15 $50 Calls Sweep (2) at the Bid: 4551 @ $0.61 vs 188 OI; Ref=$49.49,2017-09-07 11:07:00-04:00,ALKS,positive
61904.0,"Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva",2017-08-24 13:46:00-04:00,ALKS,positive
61905.0,Alkermes Initiates Rolling Submission of ALKS 5461 NDA for Major Depressive Disorder,2017-08-21 07:07:00-04:00,ALKS,negative
61906.0,Watch These 5 Huge Put Purchases In Monday Trade,2017-08-21 04:05:00-04:00,ALKS,positive
61907.0,Alkermes Option Alert: Nov 17 $45 Puts Sweep (29) at the Bid: 740 @ $1.082 vs 39 OI; Ref=$50.68,2017-08-18 14:03:00-04:00,ALKS,positive
61908.0,"Every Generation Has Its Drug: How People Are Dealing With Opioids, The New (Old) Thing",2017-08-07 11:55:00-04:00,ALKS,neutral
61909.0,"Alkermes 10-Q Shows Co. Received Subpoena From Office Of US Attorney For Docs Related To VIVITROL On Jun. 22, 2017",2017-07-27 09:39:00-04:00,ALKS,neutral
61910.0,Alkermes 10-Q Filing Just Out,2017-07-27 09:38:00-04:00,ALKS,neutral
61911.0,"Alkermes plc Reports Q2 Adj. EPS $0.01 vs $(0.01) Est., Sales $218.8M vs $216.9M Est.",2017-07-27 08:38:00-04:00,ALKS,neutral
61912.0,Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days,2017-07-05 11:01:00-04:00,ALKS,neutral
61913.0,"UPDATE: Alkermes Says 91% Of Patients Who Received ALKS 3831 Completed Study vs 89% Who Received Olanzapine, 83% Who Received Placebo",2017-06-29 16:04:00-04:00,ALKS,neutral
61914.0,"Alkermes Reports Prelim. Results From Phase 3 Antipsychotic Efficacy Study Of ALKS 3831 For Treatment Of Schizophrenia: Showed Efficacy Statistically Superior To Placebo, Similar To Olanzapine In ENLIGHTEN-1 Study",2017-06-29 16:03:00-04:00,ALKS,positive
61916.0,"Goldman Sachs Global Healthcare Conference Concludes Today, Presenters Include: Gilead, Tesaro, Ironwood Pharmaceuticals and Alkermes",2017-06-15 08:52:00-04:00,ALKS,neutral
61917.0,Leerink Swann Downgrades Alkermes plc - Ordinary Shares to Market Perform,2017-06-13 07:15:00-04:00,ALKS,positive
61918.0,Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying,2017-06-12 12:00:00-04:00,ALKS,negative
61920.0,"Jefferies Health Care Conference Begins Today, Presenters Include: Agilent Technologies, Civitas Solutions, Aeri Pharmaceuticals, Alkermes, Alnylam Pharmaceuticals, Heron Therapeutics",2017-06-06 08:47:00-04:00,ALKS,positive
61921.0,Alkermes Reports FDA Approved 2-Month ARISTADA for Treatment of Schizophrenia,2017-06-06 07:11:00-04:00,ALKS,positive
61922.0,Remider: Alkermes Has ARISTADA PDUFA Date Today,2017-06-05 08:31:00-04:00,ALKS,neutral
61923.0,Tracking The Busy June PDUFA Calendar,2017-05-30 08:58:00-04:00,ALKS,neutral
61924.0,"Companies Holding Shareholder Meetings Today Include: Paypal, Towne Bank, Alkermes, Arbutus Biopharma, Aerohive, Ionis, HSN, Hilton, Ocwen Financial, McDonald's, Lumber Liquidators, Shutterfly, & E.L.F. Beauty",2017-05-24 08:58:00-04:00,ALKS,positive
61925.0,"Alkermes Reports Q1 Adj. EPS $(0.18) vs $(0.08) Est., Sales $191.8M vs $197.3M Est.",2017-04-27 07:09:00-04:00,ALKS,neutral
61926.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,ALKS,negative
61927.0,Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient,2017-03-31 12:15:00-04:00,ALKS,neutral
61928.0,"Alkermes Shares Turn Negative Over Last Few Mins, Now Down ~0.1% Following Breaking News in MS Space",2017-03-31 11:45:00-04:00,ALKS,negative
61929.0,Alkermes Reports Initiation of Phase 3 Gastrointestinal Tolerability Study of ALKS 870 for Treatment of MS,2017-03-16 07:00:00-04:00,ALKS,neutral
61930.0,Q4 2016 Real-Time Call Brief,2017-02-15 09:42:00-05:00,ALKS,neutral
61931.0,"Alkermes Q4 EPS $0.15 vs $0.04 Est, Revenue $213.5M vs $206.4M Est",2017-02-15 07:01:00-05:00,ALKS,neutral
61932.0,Wall Street's M&A Chatter From January 19,2017-01-20 06:52:00-05:00,ALKS,neutral
61933.0,"Cantor Fitzgerald Initiates Coverage On Alkermes at Neutral, Announces $52.00 Target",2016-12-16 08:48:00-05:00,ALKS,neutral
61934.0,Alkermes Prevails In Luya Pharma IPR Challenge Against '061 Various Drug Patent,2016-11-30 13:38:00-05:00,ALKS,positive
61935.0,Recro's Late-Stage IV Meloxicam Trial Results Rocket Stock Skyward,2016-11-28 10:42:00-05:00,ALKS,neutral
61936.0,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock,2016-11-23 13:22:00-05:00,ALKS,negative
61937.0,Jefferies London Healthcare Conference Taking Place Today,2016-11-16 10:52:00-05:00,ALKS,neutral
61938.0,"Alkermes Reports Q3 EPS $(0.09) vs. Est. $(0.06), Rev. $180.2M vs. Est. $186M",2016-11-02 07:26:00-04:00,ALKS,neutral
61939.0,"Alkermes Popping On Volume, Hearing Company To Appear On Cramer's Mad Money",2016-10-26 09:56:00-04:00,ALKS,negative
61940.0,JPMorgan Upgrades Alkermes As The Company Adds To Its Already Valuable Portfolio,2016-10-21 14:38:00-04:00,ALKS,positive
61941.0,Mid-Afternoon Market Update: Skechers Falls On Earnings Miss; Reynolds American Shares Spike Higher,2016-10-21 14:30:00-04:00,ALKS,positive
61942.0,Cerecor Shares Moving In Sympathy To Positive Alkermes' Trial News,2016-10-21 13:52:00-04:00,ALKS,positive
61943.0,15 Biggest Mid-Day Gainers For Friday,2016-10-21 12:47:00-04:00,ALKS,neutral
61944.0,Mid-Day Market Update: Alkermes Surges Following Positive Data For Depression Drug Trial; Stone Energy Shares Slide,2016-10-21 12:11:00-04:00,ALKS,positive
61945.0,Alkermes Rallies Off Positive Data For Depression Drug Trial,2016-10-21 12:04:00-04:00,ALKS,neutral
61946.0,Benzinga's  Volume Movers,2016-10-21 10:36:00-04:00,ALKS,neutral
61947.0,Benzinga's Volume Movers,2016-10-21 10:36:00-04:00,ALKS,neutral
61948.0,Benzinga's   Volume  Movers,2016-10-21 10:24:00-04:00,ALKS,neutral
61949.0,Mid-Morning Market Update: Markets Open Lower; McDonald's Beats Q3 Estimates,2016-10-21 09:48:00-04:00,ALKS,negative
61950.0,Alkermes Shares Move Higher on Positive Jim Cramer Comments,2016-10-21 09:36:00-04:00,ALKS,positive
61951.0,The Market In 5 Minutes: Big Earnings In Focus And A Tobacco Giant In The Making,2016-10-21 09:09:00-04:00,ALKS,neutral
61952.0,Benzinga's Top Upgrades,2016-10-21 08:53:00-04:00,ALKS,positive
61953.0,16 Stocks Moving In Friday's Pre-Market Session,2016-10-21 08:43:00-04:00,ALKS,neutral
61954.0,JP Morgan Upgrades Alkermes plc - Ordinary Shares to Overweight,2016-10-21 06:01:00-04:00,ALKS,positive
61955.0,Alkermes Spikes 40% After Positive Data From Depression Treatment Trial,2016-10-20 17:32:00-04:00,ALKS,neutral
61956.0,Alkermes Meets Primary Endpoint In FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder,2016-10-20 16:00:00-04:00,ALKS,negative
61957.0,"Leerink Swann Assumes Alkermes at Outperform, Announces $57.00 PT",2016-10-04 07:27:00-04:00,ALKS,neutral
61958.0,Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating,2016-10-03 10:34:00-04:00,ALKS,negative
61959.0,Alkermes Initiates Clinical Study of ALKS 3831,2016-10-03 07:00:00-04:00,ALKS,neutral
61960.0,Alkermes Shares Up ~$0.45 Over Last Few Mins as Traders Passing Around Positive Mention from Motley Fool,2016-09-16 12:04:00-04:00,ALKS,positive
61961.0,"15 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-09 07:07:00-04:00,ALKS,neutral
61962.0,11 Biopharma CEOs To Follow On Twitter,2016-08-18 10:52:00-04:00,ALKS,neutral
61963.0,Alkermes Reports FDA Submission of sNDA for Two-Month Dosing Option of ARISTADA for Schizophrenia,2016-08-08 07:04:00-04:00,ALKS,neutral
61964.0,"8-K from Alkermes Shows District Court Issued Unambiguous Opinion In Favor of Co., FDA, Affirming All Respect's FDA's Decision to Approve ARISTADA for Treatment of Schizophrenia",2016-07-29 12:49:00-04:00,ALKS,positive
61965.0,"Alkermes Raises, Narrows FY16 Adj. EPS Outlook from $(0.36)-$(0.16) to $(0.23)-$(0.03) vs $(0.26) Est.",2016-07-28 07:16:00-04:00,ALKS,neutral
61966.0,"Alkermes Reports Q2 Adj. EPS $(0.01) vs $(0.10) Est., Sales $195.2M vs $174.3M Est.",2016-07-28 07:13:00-04:00,ALKS,neutral
61967.0,Cowen & Company Upgrades Alkermes to Market Perform,2016-07-26 06:14:00-04:00,ALKS,neutral
61968.0,"Barclays Adjusts Price Targets On AK Steel, CONSOL Energy And Others",2016-07-12 13:40:00-04:00,ALKS,positive
61969.0,"Barclays Sees 32% Upside In Alkermes Shares, Says 2016 Vivitrol Sales 'Could Easily Top Guidance'",2016-07-12 11:28:00-04:00,ALKS,positive
61970.0,Option Alert: ALKS Jun16 46.0 Calls: 500 @  ASK  $2.30: 517 traded vs 75 OI: $45.71 Ref,2016-05-27 12:32:00-04:00,ALKS,positive
61971.0,Benzinga's Top Initiations,2016-05-26 09:31:00-04:00,ALKS,positive
61972.0,Evercore ISI Group Initiates Coverage on Alkermes at Buy,2016-05-26 08:01:00-04:00,ALKS,neutral
61973.0,Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ALKS 4230,2016-05-25 11:47:00-04:00,ALKS,neutral
61974.0,Alkermes Reports Initiation of Phase 1 Study of ALKS 4230,2016-05-25 07:01:00-04:00,ALKS,neutral
61975.0,10 Biggest Mid-Day Gainers For Friday,2016-05-20 12:35:00-04:00,ALKS,neutral
61976.0,"Alkermes Shares Spiking, Traders Passing Around SPeculation Of Possible Sale Around $60/Shr",2016-05-20 11:38:00-04:00,ALKS,positive
61977.0,Cowen & Company Assumes Alkermes at Market Perform,2016-05-05 17:45:00-04:00,ALKS,neutral
61978.0,Shares of Alkermes Sell Off then Rebound Following FDA Safety Alert on Aripiprazole,2016-05-03 12:50:00-04:00,ALKS,positive
61979.0,Alkermes Sells Off to Low of $37.89 on Vol,2016-05-03 12:42:00-04:00,ALKS,negative
61980.0,"Alkermes Reports Q1 Adj. EPS $(0.16) vs $(0.21) Est., Sales $157M vs $153.4M Est.",2016-04-28 07:37:00-04:00,ALKS,neutral
61981.0,Alkermes to Initiate Second Trial of ALKS 7119,2016-04-28 06:58:00-04:00,ALKS,neutral
61982.0,Alkermes Reports Study on ER Naltrexone in Opioid-Dependent Patients Involved in Criminal Justice System Publised in NEJoM,2016-03-31 07:01:00-04:00,ALKS,neutral
61983.0,"Alkermes Reports Q4 EPS $(0.15) vs. Est. $(0.18), Rev. $163.1M vs. Est. $162.6M",2016-02-25 07:14:00-05:00,ALKS,neutral
61984.0,Alkermes Reports Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia,2016-02-10 07:00:00-05:00,ALKS,neutral
61985.0,7 Biotech Traders Pick Their Favorite Stocks For 2016,2016-01-28 16:53:00-05:00,ALKS,positive
61986.0,Alkermes Says Expecting Results of Phase 1 Study in 2H 2016,2016-01-25 07:06:00-05:00,ALKS,neutral
61987.0,Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes Shares Slide Following Announcement of Failed Depression Drug Trial,2016-01-21 14:42:00-05:00,ALKS,negative
61988.0,Mid-Day Market Update: US Stocks Turn Higher; Plexus Shares Gain On Strong Results,2016-01-21 12:20:00-05:00,ALKS,positive
61989.0,Stocks Hitting 52-Week Lows,2016-01-21 10:03:00-05:00,ALKS,negative
61990.0,Mid-Morning Market Update: Markets Drop; Verizon Profit Tops Estimates,2016-01-21 09:55:00-05:00,ALKS,positive
61991.0,UPDATE: Cowen & Company Lowers Alkermes PT to $50.00,2016-01-21 09:51:00-05:00,ALKS,negative
61992.0,Cowen & Company Downgrades Alkermes to Market Perform,2016-01-21 09:50:00-05:00,ALKS,neutral
61993.0,10 Stocks Moving In Thursday's Pre-Market Session,2016-01-21 08:19:00-05:00,ALKS,neutral
61994.0,Alkermes -30% Premarket @$42.33 Following Announcement of Failed Depression Drug Trial,2016-01-21 07:28:00-05:00,ALKS,negative
61995.0,"Alkermes Announces Neither Study in FORWARD-3, FORWARD-4 for ALKS 5461 in Major Depressive Disorder Met Primary Endpoint",2016-01-21 07:01:00-05:00,ALKS,negative
61996.0,Option Alert: ALKS Feb16 70.0 Calls Sweep: 550 @  ASK  $1.32: 556 traded vs 750 OI:  Earnings 2/23  $57.50 Ref,2016-01-20 09:50:00-05:00,ALKS,positive
61997.0,Option Alert: ALKS Feb16 70.0 Puts: 500 @  ASK  $2.50: 500 traded vs 1148 OI: $80.31 Ref,2015-12-28 14:10:00-05:00,ALKS,positive
61998.0,UPDATE: Alkermes Highlights Data Announced from Supportive Study in FORWARD Pivotal Program for ALKS 5461 in Major Depressive Disorder,2015-12-16 07:10:00-05:00,ALKS,negative
61999.0,"UPDATE: Alkermes Says Pivotal Programs for ALKS 3831 for Schizophrenia, ALKS 8700 for MS Initiated",2015-12-16 07:09:00-05:00,ALKS,neutral
62000.0,"Alkermes Reports Achievement of Milestones for CNS Medicines in Proprietary Product, Pipeline Portfolio",2015-12-16 07:09:00-05:00,ALKS,neutral
62001.0,"Alkermes Reports Q3 Adj. Loss of $0.18/Share vs Loss of $0.21/Share Est., Sales $152.7M vs $151.8M Est.",2015-10-29 07:02:00-04:00,ALKS,negative
62002.0,Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years,2015-09-30 04:37:00-04:00,ALKS,positive
62003.0,Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating,2015-09-02 10:58:00-04:00,ALKS,negative
62004.0,Benzinga's Volume Movers,2015-09-01 10:27:00-04:00,ALKS,neutral
62005.0,Morning Market Gainers,2015-09-01 09:44:00-04:00,ALKS,neutral
62006.0,Underappreciated Leader Skips Over Equal-Weight In Double Upgrade,2015-09-01 09:04:00-04:00,ALKS,neutral
62007.0,Benzinga's Top Upgrades,2015-09-01 09:01:00-04:00,ALKS,positive
62008.0,Benzinga's Top #PreMarket Gainers,2015-09-01 08:13:00-04:00,ALKS,positive
62009.0,"Morgan Stanley Upgrades Alkermes to Overweight, Raises PT to $85.00",2015-09-01 04:06:00-04:00,ALKS,negative
62010.0,Alkermes Offers Update on FDA Review of Aristada for Treatment of Schizophrenia: FDA Advised Co. Will Not Be Able to Close Review of NDA,2015-08-21 16:01:00-04:00,ALKS,neutral
62011.0,"Alkermes Reports Q2 Adj. Loss of $0.09/Share vs Loss of $0.10/Share Est., Sales $151.4M vs $142.8M Est.",2015-07-30 07:06:00-04:00,ALKS,negative
62012.0,Alkermes CEO Says Co Not For Sale -Wall Street Journal,2015-06-17 10:29:00-04:00,ALKS,neutral
62013.0,"Benzinga's M&A Chatter for Tuesday June 16, 2015",2015-06-16 18:04:00-04:00,ALKS,neutral
62014.0,Alkermes Declines Comment on Rumored Potential Bid from Merck,2015-06-16 11:03:00-04:00,ALKS,neutral
62015.0,"Alkermes Shares Off the Highs; Shares Moving Higher on Takeover Chatter, Upcoming Presentation of Data from Late-Stage CNS Portfolio",2015-06-16 10:17:00-04:00,ALKS,positive
62016.0,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Alkermes,2015-06-16 09:56:00-04:00,ALKS,negative
62017.0,US Stock Futures Decline Ahead Of Housing Starts Report,2015-06-16 07:22:00-04:00,ALKS,neutral
62018.0,Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical Psychopharmacology Annual Meeting,2015-06-16 07:01:00-04:00,ALKS,neutral
62019.0,Alkermes Reports Phase 3 Study Results for Aripiprazole Lauroxil Published in JCP,2015-06-09 16:01:00-04:00,ALKS,neutral
62020.0,Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Are Published in Journal of Clinical Psychiatry,2015-06-09 16:00:00-04:00,ALKS,neutral
62021.0,US Stock Futures Edge Lower; GDP Report In Focus,2015-05-29 07:47:00-04:00,ALKS,negative
62022.0,Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting of the Consortium of Multiple Sclerosis Centers,2015-05-29 07:05:00-04:00,ALKS,neutral
62023.0,Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years,2015-05-26 04:15:00-04:00,ALKS,positive
62024.0,Benzinga's Top Initiations,2015-05-21 09:07:00-04:00,ALKS,positive
62025.0,4 SMID-Cap Biotechs Barclays Just Confessed It Loves,2015-05-21 09:00:00-04:00,ALKS,positive
62026.0,Barclays Initiates Alkermes With Overweight,2015-05-21 08:49:00-04:00,ALKS,negative
62027.0,"Barclays Initiates Coverage on Alkermes at Overweight, Announces $74.00 PT",2015-05-21 04:12:00-04:00,ALKS,negative
62028.0,"Alkermes Reports Q1 Adj EPS $0.06 Vs Est -$0.03, Sales $161.2M Vs Est $146.6M",2015-04-30 07:16:00-04:00,ALKS,neutral
62029.0,Alkermes Will Start RDB 1450 Phase One Study in Q3,2015-04-13 07:12:00-04:00,ALKS,neutral
62030.0,Alkermes Reports Positive Topline Results from Full Six-Month Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia,2015-04-06 07:01:00-04:00,ALKS,positive
62031.0,"Alkermes 'Taking A Pause,' Citi Says",2015-03-27 12:14:00-04:00,ALKS,neutral
62032.0,"Citigroup Downgrades Alkermes to Neutral, Lowers PT to $71.00",2015-03-27 06:25:00-04:00,ALKS,negative
62033.0,UPDATE: Morgan Stanley Downgrades Alkermes As Good News Is Appreciated,2015-03-12 09:27:00-04:00,ALKS,positive
62034.0,"Morgan Stanley Downgrades Alkermes to Underweight, Announces $61.00 PT",2015-03-12 06:23:00-04:00,ALKS,neutral
62035.0,"Recro Pharma to Acquire IV/IM Meloxicam, Gainesville, GA GMP Manufacturing Facility, Business Unit from Alkermes for $50M",2015-03-09 06:01:00-04:00,ALKS,neutral
62036.0,US Stock Futures Edge Higher Ahead Of Economic Data,2015-03-02 07:36:00-05:00,ALKS,neutral
62037.0,"Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer's Agitation, MDD, Other CNS Diseases",2015-03-02 07:07:00-05:00,ALKS,negative
62038.0,Alkermes Announces Results From Phase 1 Study of ALKS 7106,2015-02-24 07:06:00-05:00,ALKS,neutral
62039.0,"Alkermes Reports Q4 Adj. EPS $0.11 vs $0.04 Est., Sales $175.2M vs $161.7M Est.; Sees FY15 Sales $640M-$670M vs $674.32M Est.",2015-02-24 07:03:00-05:00,ALKS,neutral
62040.0,Alkermes Shares Near High; Co Presenting at Leerink Conference,2015-02-11 10:43:00-05:00,ALKS,positive
62041.0,Alkermes Reports Positive Topline Results from Phase 1 Study of ALKS 8700 for Treatment of MS,2015-02-09 07:03:00-05:00,ALKS,positive
62042.0,Why Citigroup Placed An $85 Price Target On Shares Of Alkermes,2015-01-14 14:37:00-05:00,ALKS,positive
62043.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,ALKS,neutral
62044.0,Morning Market Gainers,2015-01-07 09:38:00-05:00,ALKS,neutral
62045.0,Benzinga's Top #PreMarket Gainers,2015-01-07 08:10:00-05:00,ALKS,positive
62046.0,"Alkermes Announces Positive Topline Results From Phase 2 Study, Primary Endpoint Met",2015-01-07 07:02:00-05:00,ALKS,positive
62047.0,Benzinga's Volume Movers,2015-01-06 10:45:00-05:00,ALKS,neutral
62048.0,Alkermes Initiates Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia,2014-12-15 07:07:00-05:00,ALKS,neutral
62049.0,3 Biotech ETFs Rally On Merger News,2014-12-08 17:43:00-05:00,ALKS,neutral
62050.0,Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue,2014-11-11 04:15:00-05:00,ALKS,positive
62051.0,Alkermes plc Reports Q3 EPS of $0.03 vs $0.02 Est; Revenue of $160.0M vs $155.53M Est,2014-10-29 07:05:00-04:00,ALKS,neutral
62052.0,Alkermes' NDA for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by FDA ,2014-10-22 07:04:00-04:00,ALKS,positive
62053.0,Bank Of America Q3 Small & Mid-Cap Biotech Preview,2014-10-20 16:58:00-04:00,ALKS,neutral
62054.0,"Alkermes PLC Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic",2014-09-03 07:04:00-04:00,ALKS,positive
62055.0,Alkermes Initiates Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain ,2014-08-26 07:10:00-04:00,ALKS,negative
62056.0,US Stock Futures Rise Ahead Of Economic Data,2014-08-25 07:28:00-04:00,ALKS,neutral
62057.0,Alkermes Submits NDA to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia ,2014-08-25 07:04:00-04:00,ALKS,neutral
62058.0,"Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For Alkermes plc",2014-08-14 09:40:00-04:00,ALKS,positive
62059.0,Alkermes plc Lowers FY2014 EPS Guidance from $0.41-0.54 to $0.19-0.32 vs $0.51 Est,2014-07-31 07:12:00-04:00,ALKS,negative
62060.0,Alkermes plc Reports Q2 EPS of $0.11 vs $0.14 Est; Revenue of $153.40M vs $147.51M Est,2014-07-31 07:11:00-04:00,ALKS,neutral
62061.0,Alkermes Says on Track for Aripiprazole Lauroxil NDA Submission in Q3 2014,2014-07-31 07:07:00-04:00,ALKS,neutral
62062.0,Alkermes Announces Initiation of Clinical Study For ALKS 5461,2014-07-30 07:00:00-04:00,ALKS,neutral
62063.0,Alkermes Announces Initiation of Phase 1 Study of ALKS 8700,2014-07-17 07:00:00-04:00,ALKS,neutral
62064.0,Alkermes Reports Notices of Allowance for US Patents for Four CNS Pipeline Candidates,2014-07-09 07:06:00-04:00,ALKS,neutral
62065.0,Alkermes Announces Aripiprazole Met Endpoint,2014-06-18 07:02:00-04:00,ALKS,neutral
62066.0,"Cramer Says Eaton, TE Connectivity, Pentair, Tyco, Alkermes, Jazz Pharma, Weatherford May be Takeover Targets, Similar Situations to Covidien Regarding Tax Benefit",2014-06-16 18:23:00-04:00,ALKS,positive
62067.0,"Alkermes Reports Commencement of FORWARD-3, FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461",2014-06-10 07:04:00-04:00,ALKS,neutral
62068.0,Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest Revenue,2014-04-30 07:32:00-04:00,ALKS,positive
62069.0,"Mizuho Securities Upgrades Alkermes plc to Buy, Raises PT to $61.00",2014-04-10 07:53:00-04:00,ALKS,positive
62070.0,Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins,2014-04-08 16:54:00-04:00,ALKS,neutral
62071.0,Mid-Afternoon Market Update: Markets Recover Slightly as Coal Shows Strength,2014-04-08 15:46:00-04:00,ALKS,positive
62072.0,Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On Lower Forecast,2014-04-08 13:22:00-04:00,ALKS,positive
62073.0,Benzinga's Volume Movers,2014-04-08 10:55:00-04:00,ALKS,neutral
62074.0,Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit Outlook,2014-04-08 10:29:00-04:00,ALKS,positive
62075.0,Morning Market Movers ,2014-04-08 09:38:00-04:00,ALKS,neutral
62076.0,UPDATE: Alkermes Shares Rise 7% Premarket on Release of Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil,2014-04-08 08:42:00-04:00,ALKS,positive
62077.0,Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil,2014-04-08 07:01:00-04:00,ALKS,positive
62078.0,Benzinga's Top Initiations,2014-04-02 07:49:00-04:00,ALKS,positive
62079.0,"Credit Suisse Initiates Coverage on Alkermes plc at Outperform, Announces $57.00 PT",2014-04-02 06:49:00-04:00,ALKS,positive
62080.0,Alkermes Announces Initiation of ALKS-5461 PIVOTAL Clinical Trial,2014-03-06 07:07:00-05:00,ALKS,neutral
62081.0,Alkermes plc Sees FY2014 EPS $0.41-0.54; Sees Sales $580.0M-610.0M,2014-02-27 07:15:00-05:00,ALKS,neutral
62082.0,Alkermes plc Reports Q4 EPS of $0.27 vs $0.20 Est; Revenue of $154.50M vs $142.93M Est,2014-02-27 07:14:00-05:00,ALKS,neutral
62083.0,Alkermes Files Prospectus for 5.9M Shares,2014-01-13 07:45:00-05:00,ALKS,positive
62084.0,Alkermes Announces Advances in Late-Stage CNS Pipeline ,2014-01-08 07:02:00-05:00,ALKS,neutral
62085.0,Alkermes Receives Notice of Allowance of US Patent for Novel Fumarate Prodrug for MS,2014-01-06 07:04:00-05:00,ALKS,positive
62086.0,Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 at 52nd Annual ACNP Meeting ,2013-12-09 07:13:00-05:00,ALKS,neutral
62087.0,UBS Downgrades Alkermes plc to Neutral,2013-12-05 07:28:00-05:00,ALKS,neutral
62088.0,CORRECTION: Alkermes plc Reports Q2 EPS of $0.22 vs $0.23 Est; Revenue of $139.80M vs $137.48M Est,2013-10-31 07:15:00-04:00,ALKS,neutral
62089.0,Alkermes plc Reports Q3 EPS of $0.22 vs $0.23 Est; Revenue of $139.80M vs $137.48M Est,2013-10-31 07:15:00-04:00,ALKS,neutral
62090.0,UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities,2013-10-17 09:26:00-04:00,ALKS,positive
62091.0,"Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development Program",2013-10-09 07:05:00-04:00,ALKS,positive
62092.0,Morgan Stanley Downgrades Alkermes plc to Equalweight,2013-10-01 06:55:00-04:00,ALKS,neutral
62093.0,Top 4 Stocks In The Drug Delivery Industry With The Highest Cash,2013-09-20 04:16:00-04:00,ALKS,positive
62094.0,Moody's Upgrades Alkermes to Ba3; Outlook Positive,2013-08-01 13:33:00-04:00,ALKS,positive
62095.0,UPDATE: Bank of America Lowers PO on Alkermes on Reduced Bydureon Forecast,2013-06-19 11:10:00-04:00,ALKS,negative
62096.0,Alkermes Issues Positive Results from Phase 2 Study of ALKS 5461,2013-05-31 09:51:00-04:00,ALKS,positive
62097.0,Alkermes Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder Met Primary Endpoint,2013-05-31 07:04:00-04:00,ALKS,negative
62098.0,Leerink Swann Initiates Coverage on Alkermes plc at Outperform,2013-05-29 08:27:00-04:00,ALKS,neutral
62099.0,A Peek Into The Market Before The Trading Starts,2013-05-28 07:21:00-04:00,ALKS,neutral
62100.0,Alkermes Announces Positive Results from Phase 1 Study of ALKS 3831 Treatment for Schizophrenia ,2013-05-28 07:07:00-04:00,ALKS,positive
62101.0,MKM Partners Downgrades Alkermes plc to Sell,2013-05-24 08:34:00-04:00,ALKS,neutral
62102.0,Argus Research Downgrades Alkermes plc to Sell,2013-05-24 08:33:00-04:00,ALKS,neutral
62103.0,Alkermes plc Reports Q4 EPS of $0.40 Which May Not Compare $0.17 Est,2013-05-23 07:04:00-04:00,ALKS,neutral
62104.0,Top 4 Stocks In The Drug Delivery Industry With The Lowest PEG Ratio,2013-05-22 04:28:00-04:00,ALKS,negative
62105.0,"The Week Ahead: Full Slate of Economic Data; Earnings From Cisco, Wal-Mart and Deere ",2013-05-10 21:59:00-04:00,ALKS,neutral
62106.0,UPDATE: Bank of America Downgrades Alkermes to Underperform on ALKS-5461 Market Opportunity,2013-04-26 09:24:00-04:00,ALKS,positive
62107.0,"Bank of America Downgrades Alkermes plc to Underperform, Raises PO to $29.00",2013-04-26 06:27:00-04:00,ALKS,negative
62108.0,Lazard Capital Markets Downgrades Alkermes plc to Neutral,2013-04-22 07:51:00-04:00,ALKS,neutral
62109.0,Mizuho Downgraded Alkermes Following 16% Surge on Wednesday,2013-04-18 10:59:00-04:00,ALKS,neutral
62110.0,"Market Wrap for Wednesday, April 17: Stocks Plunge Again Along With Euro ",2013-04-17 16:27:00-04:00,ALKS,neutral
62111.0,"Mid-Afternoon Market Update: Markets Remain Down, ABIOMED Rises",2013-04-17 15:35:00-04:00,ALKS,neutral
62112.0,"Mid-Day Market Update: Cirrus Logic Plunges On Weak Forecast, Atlas Energy Rises",2013-04-17 12:51:00-04:00,ALKS,negative
62113.0,Stocks Hitting 52-Week Highs,2013-04-17 12:14:00-04:00,ALKS,neutral
62114.0,"Mid-Morning Market Update: Markets Move Lower, Bank of America Posts Downbeat Q1 Profit",2013-04-17 10:17:00-04:00,ALKS,positive
62115.0,Alkermes Announces Positive Phase 2 Results from Clinical Study of ALKS 5461 for Major Depressive Disorder ,2013-04-17 07:11:00-04:00,ALKS,negative
62116.0,"Alkermes Reducing Headcount by 130 Jobs, Sees Restructuring Charge $12.5M",2013-04-09 10:05:00-04:00,ALKS,neutral
62117.0,Alkermes Maintains FY13 Adj. Net Income Guidance of $135-155M,2013-02-19 16:26:00-05:00,ALKS,neutral
62118.0,"Bank of America Downgrades Alkermes plc to Neutral, Raises PO to $24.00",2013-02-01 06:31:00-05:00,ALKS,negative
62119.0,"Bank of America Downgrades Alkermes plc to undefined, Raises PO to $24.00",2013-02-01 06:28:00-05:00,ALKS,negative
62120.0,"Elan Selling Remaining Stake in Alkermes, 7.75M Shares",2013-01-31 16:29:00-05:00,ALKS,positive
62121.0,Alkermes plc Raises FY2013 EPS Guidance from $0.88-1.02 to $0.99-1.13 vs $0.95 Est,2013-01-31 07:17:00-05:00,ALKS,neutral
62122.0,Alkermes plc Reports Q3 EPS of $0.34 vs $0.23 Est,2013-01-31 07:17:00-05:00,ALKS,neutral
62123.0,"MKM Partners Downgrades Alkermes plc to Neutral, Maintains $23.00 PT",2013-01-23 10:48:00-05:00,ALKS,neutral
62124.0,UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking For Better Entry  ,2013-01-17 13:12:00-05:00,ALKS,positive
62125.0,"Credit Suisse Initiates Coverage on Alkermes plc at Neutral, Announces $24.00 PT",2013-01-17 07:11:00-05:00,ALKS,positive
62126.0,"Citigroup Maintains Buy on Alkermes plc, Raises PT to $30.00",2013-01-15 09:03:00-05:00,ALKS,neutral
62127.0,Top 4 Stocks In The Drug Delivery Industry With The Highest EPS Estimates For The Next Quarter,2013-01-14 02:30:00-05:00,ALKS,positive
62128.0,Editor of Little Bear Blog is Adding to Alkermes Long Position,2013-01-10 12:58:00-05:00,ALKS,neutral
62129.0,UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities  ,2013-01-10 08:19:00-05:00,ALKS,neutral
62130.0,"Morgan Stanley Upgrades Alkermes plc to Overweight, Raises PT to $26.00",2013-01-10 06:47:00-05:00,ALKS,negative
62131.0,"Alkermes Shares Spiking Above 20-Day SMA, $21 Level Following CEO Appearance on CNBC, Said Optimistic for Raise in Vivitrol Use by Prisoners",2013-01-07 10:36:00-05:00,ALKS,positive
62132.0,Alkermes Announces Notice of Allowance of USPTO Application for Aripiprazole Lauroxil,2013-01-03 07:18:00-05:00,ALKS,neutral
62133.0,Alkermes Announces Positive Results from Phase 1 Study of ALKS 3831,2013-01-03 07:14:00-05:00,ALKS,positive
62134.0,UPDATE: Morgan Stanley Initiates Alkermes at Equal-Weight on Commercialization Visibility  ,2012-11-27 13:56:00-05:00,ALKS,neutral
62135.0,"Morgan Stanley Initiates Coverage Alkermes at Equalweight, Announces PT of $21",2012-11-27 06:27:00-05:00,ALKS,neutral
62136.0,"Morgan Stanley Initiates Coverage Alkermes at Equalweight, Announces PT of $21",2012-11-27 06:26:00-05:00,ALKS,neutral
62137.0,"Mizuho Initiated Coverage on Alkermes at Buy, Announces PT of $27",2012-11-16 10:20:00-05:00,ALKS,neutral
62138.0,Alkermes' Corporate Presentation to be Webcast at Two Upcoming Conferences  ,2012-11-07 16:02:00-05:00,ALKS,neutral
62139.0,"JP Morgan Maintains Alkermes at Overweight, Raises PT from $25 to $26",2012-11-01 15:19:00-04:00,ALKS,neutral
62140.0,"Alkermes Boosts FY Sales Outlook from $490-530M to $510-540M vs $516.3M Est, EPS from $(0.15)-(0.30) to $0.00-(0.11) vs $(0.14) Est",2012-11-01 10:56:00-04:00,ALKS,positive
62141.0,Alkermes Reports Q2 EPS $0.17 vs $0.11 Est; Revenues $124M vs $121.62M Est,2012-11-01 10:45:00-04:00,ALKS,neutral
62142.0,"UPDATE: Alkermes Guides FY EPS $0.69-0.84, Had Seen $0.62-0.77",2012-09-25 16:04:00-04:00,ALKS,neutral
62143.0,Alkermes Closes Debt Refinancing,2012-09-25 16:01:00-04:00,ALKS,negative
62144.0,Alkermes Said to be Adding $75M Term Loan Due 2016; 7 Year Term Loan Reduced to $300M From $375M -Bloomberg,2012-09-14 11:43:00-04:00,ALKS,neutral
62145.0,"Jefferies Reiterates Buy Rating, $24 PT on Alkermes",2012-07-18 12:13:00-04:00,ALKS,neutral
62146.0,Alkermes Receives Positive Mad Money/Jim Cramer Mention -CNBC,2012-07-17 19:46:00-04:00,ALKS,positive
62147.0,UPDATE: J.P. Morgan Lowers Alkermes' PT,2012-05-31 09:14:00-04:00,ALKS,negative
62148.0,UPDATE: Alkermes Says Alkermes Phase 2 Study of ALKS 37 Did Not Satisfy Pre-Specified Criteria; Will Not Advance to Phase 3 ,2012-05-30 16:02:00-04:00,ALKS,negative
62149.0,Alkermes Announces Results from Phase 2 Study of ALKS 37 for Treatment of Opioid-Induced Constipation   ,2012-05-30 16:00:00-04:00,ALKS,neutral
62150.0,Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug Evaluation Unit Meeting   ,2012-05-29 16:00:00-04:00,ALKS,positive
62151.0,"UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for Alkermes",2012-05-18 13:09:00-04:00,ALKS,negative
62152.0,Alkermes Reports Q4 EPS $0.12 vs $-0.16 Est; Revenues $130.5M vs $125.88M Est,2012-05-17 07:02:00-04:00,ALKS,neutral
62153.0,Alkermes CEO Pops: 'The Difficult Part of Being a Pioneer is You Need to Blaze Your Own Trail',2012-05-10 18:24:00-04:00,ALKS,negative
62154.0,Alkermes CEO Pops: 'Biotech is a Good Place for Large Companies to Hunt Because They Need New Drugs',2012-05-10 18:22:00-04:00,ALKS,positive
62155.0,Alkermes CEO Pops: 'We are Inventing New Drugs That Will Add Value Like Lipitor Has Done for Years',2012-05-10 18:21:00-04:00,ALKS,positive
62156.0,Jim Cramer Interviews CEO Richard F. Pops of Alkermes on Mad Money,2012-05-10 18:16:00-04:00,ALKS,negative
62157.0,PREVIEW: Jim Cramer to Interview CEO of Alkermes on Mad Money,2012-05-10 18:11:00-04:00,ALKS,negative
62158.0,"Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary Shares Held by Elan",2012-03-08 09:15:00-05:00,ALKS,positive
62159.0,Alkermes Reports Secondary Offering of 13.9M Shares Held by Elan,2012-03-07 16:57:00-05:00,ALKS,positive
62160.0,"Alkermes Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan",2012-03-07 16:33:00-05:00,ALKS,positive
62161.0,Market Roundup,2012-03-05 12:08:00-05:00,ALKS,neutral
62162.0,Alkermes Appoints Mark Stejbach as Chief Commercial Officer,2012-03-05 07:02:00-05:00,ALKS,neutral
62163.0,Alkermes Files Resale Shelf Registration in Connection with Elan Shareholder Agreement   ,2012-02-16 16:16:00-05:00,ALKS,positive
62164.0,"BYDUREON™, First and Only Once-Weekly Type 2 Diabetes Treatment, Now Available in U.S. Pharmacies ",2012-02-13 08:04:00-05:00,ALKS,neutral
62165.0,Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval,2012-02-02 13:49:00-05:00,ALKS,positive
62166.0,Alkermes Initiates Open-Label Pilot Study of VIVITROL to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence   ,2012-01-31 07:01:00-05:00,ALKS,negative
62167.0,"Benzinga's M&A Chatter for Monday January 30, 2012",2012-01-30 17:53:00-05:00,ALKS,neutral
62168.0,Benzinga's Top Pre-Market Gainers,2012-01-30 08:14:00-05:00,ALKS,positive
62169.0,Trading Resumed in Alkermes,2012-01-27 16:15:00-05:00,ALKS,neutral
62170.0,"Amylin Pharmaceuticals, Alkermes Resume Trading ",2012-01-27 16:15:00-05:00,ALKS,neutral
62171.0,"PREVIEW: Amylin Pharmaceuticals, Alkermes to Resume Trading at 4:15pm",2012-01-27 15:58:00-05:00,ALKS,neutral
62172.0,"UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes ",2012-01-27 15:44:00-05:00,ALKS,positive
62173.0,"UPDATE: Amylin, Alkermes Drug Approved by FDA",2012-01-27 14:39:00-05:00,ALKS,positive
62174.0,"UPDATE: No Decision Made by FDA on Amylin, Alkermes -Bloomberg",2012-01-27 14:35:00-05:00,ALKS,negative
62175.0,"Amylin, Alkermes Win US Clearance for Weekly Diabetes Shot",2012-01-27 14:32:00-05:00,ALKS,positive
62176.0,"Alkermes Halted, News Pending",2012-01-27 13:54:00-05:00,ALKS,neutral
62177.0,Benzinga's Volume Gainers,2012-01-25 15:35:00-05:00,ALKS,neutral
62178.0,Best Specialty Pharma Stocks Picked by UBS,2012-01-20 18:27:00-05:00,ALKS,positive
62179.0,CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous Story Clarified,2012-01-11 16:26:00-05:00,ALKS,positive
62180.0,"Financial Breakfast: Morning News Summary for January 4, 2012",2012-01-04 07:25:00-05:00,ALKS,neutral
62181.0,Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder,2012-01-04 07:00:00-05:00,ALKS,negative
62182.0,Alkermes Initiates Phase 3 Clinical Study of ALKS 9070 for Treatment of Schizophrenia   ,2011-12-19 08:00:00-05:00,ALKS,neutral
62183.0,Jefferies Maintains Buy Rating and $21 PT on Alkermes ,2011-12-02 10:08:00-05:00,ALKS,neutral
62184.0,"Financial Breakfast: Morning News Summary for November 9, 2011",2011-11-09 07:48:00-05:00,ALKS,neutral
62185.0,Alkermes Announces New Long-Term Data on VIVITROL Showed Sustained Efficacy and Safety over 18 Months of Treatment   ,2011-11-09 07:07:00-05:00,ALKS,positive
62186.0,"Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",2011-10-17 08:40:00-04:00,ALKS,negative
62187.0,Mad Money Lightning Round: Cramer Likes Alkermes,2011-10-12 04:21:00-04:00,ALKS,negative
62188.0,Alkermes Announces Initiation of Phase 2b Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation   ,2011-10-03 07:04:00-04:00,ALKS,neutral
62189.0,Benzinga's Top Upgrades,2011-09-26 07:31:00-04:00,ALKS,positive
62190.0,A Peek Into The Market Before The Trading Starts,2011-09-26 07:29:00-04:00,ALKS,neutral
62191.0,UPDATE: Jefferies Upgrades Alkermes to Buy,2011-09-26 07:21:00-04:00,ALKS,neutral
62192.0,"Jefferies Upgrades Alkermes to Buy, PT Raised to $21",2011-09-26 05:56:00-04:00,ALKS,neutral
62193.0,UPDATE: Goldman Sachs Raises PT on Alkermes to $17,2011-09-23 07:43:00-04:00,ALKS,neutral
62194.0,Goldman Sachs Raises PT on Alkermes to $17,2011-09-23 07:04:00-04:00,ALKS,neutral
62195.0,"Merger Arbitrage Mondays – September 19, 2011",2011-09-12 13:07:00-04:00,ALKS,neutral
62196.0,A Peek Into The Market Before The Trading Starts,2011-09-12 07:21:00-04:00,ALKS,neutral
62197.0,"Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors",2011-09-12 07:01:00-04:00,ALKS,negative
62198.0,Alkermes Announces Shareholder Vote in Favor of Merger with Elan Drug Technologies   ,2011-09-08 10:43:00-04:00,ALKS,positive
62199.0,"UBS Upgrades Alkermes, Raises PT",2011-08-23 10:44:00-04:00,ALKS,neutral
62200.0,"Bydureon FDA Action Date Set For January 28, 2012",2011-08-10 16:18:00-04:00,ALKS,neutral
62201.0,Options Brief: Alkermes,2011-08-02 10:11:00-04:00,ALKS,neutral
62202.0,Jefferies Comments on Acquisition at Alkermes,2011-08-02 07:07:00-04:00,ALKS,neutral
62203.0,Alkermes Reports Q1 EPS $0.02 May Not be Comparable to $(0.12) Est; Revenues $61.9M vs $52.67M Est			,2011-08-01 16:02:00-04:00,ALKS,neutral
62204.0,Earnings Scheduled For August 1,2011-08-01 03:31:00-04:00,ALKS,neutral
62205.0,BYDUREON™ Reply Submitted to FDA,2011-07-28 08:02:00-04:00,ALKS,neutral
62207.0,Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter,2011-07-18 14:55:00-04:00,ALKS,neutral
62208.0,Alkermes Forecasts 2012 Pro Forma Revenues of $460M to $480M,2011-07-18 14:07:00-04:00,ALKS,neutral
62209.0,Alkermes Spiking Higher on Raised Guidance,2011-07-18 14:06:00-04:00,ALKS,neutral
62210.0,Lazard Capital Upgrades Alkermes from Neutral to Buy; Stock Jumps Over 2% on the Open,2011-07-13 09:42:00-04:00,ALKS,neutral
62211.0,Stocks to Watch for Monday 07/11/11: Fresh 52 Week Highs and Lows,2011-07-10 18:15:00-04:00,ALKS,positive
62212.0,Goldman Sachs Reiterates Sell on AMLN and Neutral on ALKS,2011-07-08 09:24:00-04:00,ALKS,neutral
62213.0,Benzinga's Top Pre-Market NASDAQ Gainers,2011-07-08 08:18:00-04:00,ALKS,positive
62214.0,Alkermes Announces Positive Results from Clinical Study of ALKS 9070,2011-06-30 08:01:00-04:00,ALKS,positive
62215.0,"Pharmacoeconomic Value of Addiction Treatments, Including VIVITROL, Published in Leading Healthcare Policy Journal ",2011-06-27 08:11:00-04:00,ALKS,positive
62216.0,"News Summary for June 21, 2011",2011-06-21 08:06:00-04:00,ALKS,neutral
62217.0,A Peek Into The Market Before The Trading Starts,2011-06-21 07:25:00-04:00,ALKS,neutral
62218.0,Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe   ,2011-06-21 07:00:00-04:00,ALKS,neutral
62219.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,ALKS,positive
62220.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,ALKS,negative
62221.0,"Calls Purchased on Alkermes, Inc. ",2011-05-20 10:38:00-04:00,ALKS,neutral
62222.0,J.P. Morgan Increases PT On ALKS To $21,2011-05-19 09:02:00-04:00,ALKS,neutral
62223.0,Jefferies & Company Reports on Alkermes,2011-05-19 07:48:00-04:00,ALKS,neutral
62224.0,JP Morgan Raises PT On Alkermes To $21,2011-05-19 07:33:00-04:00,ALKS,positive
62225.0,Alkermers Reports EPS of $(0.14) vs. $(0.14) Estimate; Revenues $51.13M vs. $46.73M Estimate ,2011-05-18 16:02:00-04:00,ALKS,neutral
62226.0,"Earnings Scheduled For May 18 (BJ, DE, TGT, AAP, SPLS, ROST, JACK, LTD, CHS, ABMD, PETM, BRC, HOTT, ANF, ALKS, EV, NTES, CCM, SNPS)",2011-05-18 01:16:00-04:00,ALKS,neutral
62227.0,"Most Popular Stocks Right Now on 5/16/11- CNOZ, MBYL, ALKS, BAC, DANR, PRM, HPNN, LOW, BRP, PSP, WNWG",2011-05-16 08:29:00-04:00,ALKS,positive
62228.0,Alkermes Rises 3% Ahead Of Earnings (ALKS),2011-05-12 14:56:00-04:00,ALKS,neutral
62229.0,"Market Upgrades on 5/10/11- HEOP, KNDL, KWK, LPX, MR, ROSE, SAM, SKS, VIA.B, ALKS, BAP, COLB, CPN, FE, GBL, GTXI",2011-05-10 10:49:00-04:00,ALKS,neutral
62230.0,UPDATE: Hapoalim Raising Price Target On Alkermes (ALKS),2011-05-09 12:38:00-04:00,ALKS,neutral
62231.0,"Benzinga's Volume Movers (ALKS, NUAN, BSFT, ROSE)",2011-05-09 10:26:00-04:00,ALKS,neutral
62232.0,"US Stock Futures Up; Gold Futures Surge To $1,506.50 an ounce",2011-05-09 06:56:00-04:00,ALKS,neutral
62233.0,"Market updates: Greece, Chubu Electric, Munich Re, BARC, LLOY, CNA, TCG, ISAT, SRP, ELN, ALKS, VITA, BHP, HBC, LMI",2011-05-09 06:08:00-04:00,ALKS,neutral
62234.0,"CEOWORLD Daily Business Roundup- JNJ, CHK, AMD, T, AXP, AAPL, INTC, JPM, GOOG, LLY, CSCO…",2011-04-16 07:47:00-04:00,ALKS,neutral
62235.0,"Top Percentage Gainers and Losers as of 10am 4/15/11 (AGO, OPXA, MBI, AMLN, ABMD, CTCT, CRUS, GGC, OTIV, SFG, BAC, LLY, ALKS)",2011-04-15 10:09:00-04:00,ALKS,negative
62236.0,"BYDUREON Recommended For Approval In Europe (LLY, ALKS)                                                ",2011-04-15 08:59:00-04:00,ALKS,positive
62237.0,"Eli Lilly, Amylin Pharmaceuticals, and Alkermes Announce BYDUREON Recommended for Approval in Europe ",2011-04-15 07:18:00-04:00,ALKS,positive
62238.0,Alkermes' BYDUREON Receives Approval In Europe (ALKS),2011-04-15 07:08:00-04:00,ALKS,positive
62239.0,"Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study",2011-03-03 08:04:00-05:00,ALKS,neutral
62240.0,"Trading Halted: Alkermes, News Pending ",2011-03-03 07:56:00-05:00,ALKS,neutral
62241.0,Alkermes Announces Positive Preliminary Results from Phase 2 Study of ALKS 37 ,2011-02-15 08:22:00-05:00,ALKS,positive
62242.0,Options Brief: Alkermes (ALKS),2011-02-04 13:37:00-05:00,ALKS,neutral
62243.0,Hapoalim Reiterates Buy on Alkermes (ALKS),2011-02-04 10:54:00-05:00,ALKS,neutral
62244.0,Alkermes Reports Third Quarter Fiscal 2011 Financial Results: Loss of $0.12 Per Share,2011-02-03 16:03:00-05:00,ALKS,neutral
62245.0,Earnings Preview: Alkermes - Analyst Blog,2011-01-31 13:03:00-05:00,ALKS,neutral
62246.0,Earnings Preview: Alkermes - Analyst Blog,2011-01-31 12:30:00-05:00,ALKS,neutral
62247.0,Cost Control Helps Amylin Cut Loss - Analyst Blog,2011-01-27 10:31:00-05:00,ALKS,negative
62248.0,Cost Control Helps Amylin Cut Loss - Analyst Blog,2011-01-27 10:15:00-05:00,ALKS,negative
62249.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 10:01:00-05:00,ALKS,negative
62250.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 09:45:00-05:00,ALKS,negative
62251.0,Alkermes Elects Wendy L. Dixon to Board of Directors   ,2011-01-18 08:04:00-05:00,ALKS,neutral
62252.0,Long ALKS At $12.68,2011-01-11 11:41:00-05:00,ALKS,neutral
62253.0,"Top 4 Small-Cap Stocks In The Drug Delivery Industry With The Highest Cash (ALKS, PETS, KV-A, MTXX)",2011-01-07 01:10:00-05:00,ALKS,positive
62254.0,Label Expansion Sought for Byetta - Analyst Blog,2010-12-23 09:03:00-05:00,ALKS,neutral
62255.0,Label Expansion Sought for Byetta - Analyst Blog,2010-12-23 08:15:00-05:00,ALKS,neutral
62256.0,Rolling BLA for AMLN's Metreleptin - Analyst Blog,2010-12-21 09:36:00-05:00,ALKS,neutral
62257.0,Rolling BLA for AMLN's Metreleptin - Analyst Blog,2010-12-21 09:15:00-05:00,ALKS,neutral
62258.0,Good News for Alkermes' Pipeline - Analyst Blog,2010-12-09 11:33:00-05:00,ALKS,positive
62259.0,Good News for Alkermes' Pipeline - Analyst Blog,2010-12-09 10:47:00-05:00,ALKS,positive
62260.0,Amylin Stays Neutral - Analyst Blog,2010-11-24 12:12:00-05:00,ALKS,neutral
62261.0,Amylin Stays Neutral - Analyst Blog,2010-11-24 06:20:00-05:00,ALKS,neutral
62262.0,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk       - Press Releases",2010-11-12 10:33:00-05:00,ALKS,positive
62263.0,"Revenues Rise at ALKS, View Lowered - Analyst Blog",2010-11-08 17:03:00-05:00,ALKS,negative
62264.0,Hapoalim Securities Has $16 Target On Alkermes (ALKS),2010-11-05 09:36:00-04:00,ALKS,positive
62265.0,Alkermes Reports Second Quarter Fiscal 2011 Financial Results: Loss Per Share of $0.08,2010-11-04 16:16:00-04:00,ALKS,neutral
62266.0,"Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (HSP, ELN, NKTR, ALKS)",2010-11-02 04:24:00-04:00,ALKS,positive
62267.0,Hapoalim Securities Defends Alkermes (ALKS),2010-10-21 15:24:00-04:00,ALKS,positive
62268.0,"Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)",2010-10-20 09:33:00-04:00,ALKS,negative
62269.0,"Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)",2010-10-20 09:24:00-04:00,ALKS,negative
62270.0,"Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)",2010-10-20 09:08:00-04:00,ALKS,negative
62271.0,"Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)",2010-10-20 09:00:00-04:00,ALKS,negative
62272.0,Amylin Pharmaceuticals Crushed In Pre-Market (AMLN),2010-10-20 07:35:00-04:00,ALKS,negative
62273.0,FDA Nod for Alkermes' Vivitrol - Analyst Blog,2010-10-18 09:15:00-04:00,ALKS,neutral
62274.0,"Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (ELN, HSP, NKTR, ALKS)",2010-10-14 04:42:00-04:00,ALKS,positive
62275.0,Jefferies & Company Projects Alkermes Sales of $40M,2010-10-13 08:42:00-04:00,ALKS,neutral
62276.0,"Benzinga's After Hours Gainers (INTC, ALKS, CSCO, CSX, ODP)",2010-10-12 19:22:00-04:00,ALKS,neutral
62277.0,Readers Pick Drug Approval Winners & Losers,2010-10-04 07:15:00-04:00,ALKS,positive
62278.0,"Benzinga's Top Pre-Market NASDAQ Gainers (GYMB, CCME, ALKS, ARMH)",2010-10-01 09:08:00-04:00,ALKS,positive
62279.0,"PRX, ALKS, Initiated At Buy",2010-09-30 10:23:00-04:00,ALKS,neutral
62280.0,Thumbs Up for ALKS Drug - Analyst Blog,2010-09-17 15:39:00-04:00,ALKS,neutral
62281.0,"Benzinga's Volume Movers (UTHR, GSM, ALKS, ORCL)",2010-09-17 14:42:00-04:00,ALKS,neutral
62282.0,Hapoalim Likes Alkermes After FDA Panel Recommendation (ALKS),2010-09-17 12:31:00-04:00,ALKS,positive
62283.0,"Benzinga's Top Pre-Market NASDAQ Gainers (CRXL, ALKS, CCME, RIMM)",2010-09-17 09:12:00-04:00,ALKS,positive
62284.0,21 Drugs Facing FDA Approval Decisions,2010-08-31 08:51:00-04:00,ALKS,positive
62285.0,"Mad Money Lightning Round OT (SOLR, ZION, ALKS)",2010-08-18 19:41:00-04:00,ALKS,negative
62286.0,Revenues Dip at Alkermes - Analyst Blog,2010-08-09 17:52:00-04:00,ALKS,neutral
62287.0,"Stocks Hitting 52-Week Highs (ALKS, BIDU, CHRW, ENDP)",2010-08-09 14:47:00-04:00,ALKS,neutral
62288.0,"Hapoalim Rates Alkermes ""Buy""",2010-08-06 08:23:00-04:00,ALKS,neutral
62289.0,Alkermes Reports First Quarter Fiscal 2011 Financial Results,2010-08-05 16:50:00-04:00,ALKS,neutral
62290.0,Zacks #5 Rank Additions for Tuesday  - Tale of the Tape,2010-08-03 09:11:00-04:00,ALKS,neutral
62291.0,"Low Yields, Consumer Confidence, Income Impact 06-28-2010",2010-06-28 18:45:00-04:00,ALKS,positive
62292.0,Four Sectors Worth Watching  06-28-2010,2010-06-28 14:52:00-04:00,ALKS,positive
62293.0,Downside Purchased on Alkermes Inc. (ALKS),2010-06-28 13:00:00-04:00,ALKS,negative
62294.0,"Top 4 Stocks In The Drug Delivery Industry With The Highest Gross Margin (BVF, ALKS, MTXX, NKTR)",2010-06-25 06:01:00-04:00,ALKS,negative
62295.0,"Benzinga’s Volume Movers (ZUMZ, AMLN, ALKS, HTWR)",2010-06-18 12:06:00-04:00,ALKS,neutral
62296.0,Calls Purchased on Alkermes (ALKS),2010-06-18 10:58:00-04:00,ALKS,neutral
62297.0,"Market Round-Up (GOOG, ALKS)",2010-05-14 15:40:00-04:00,ALKS,neutral
62298.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,ALKS,positive
62299.0,"Stocks That Created New 52-Week Highs (AIRT, ALKS, ALLT, ATEC, AMIC)",2010-03-15 16:20:00-04:00,ALKS,positive
62300.0,"Benzinga’s Volume Movers (AMLN, ALKS, FNSR, PEGA, BIDU)",2010-03-15 16:17:00-04:00,ALKS,neutral
62301.0,US Stock Futures Fall On Concerns Over Chinese Monetary Policy,2010-03-15 09:55:00-04:00,ALKS,neutral
62302.0,"Benzinga’s News Roundup (PEP, ALKS, MRK)",2010-03-15 09:37:00-04:00,ALKS,neutral
62303.0,"Benzinga’s Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)",2010-03-15 09:26:00-04:00,ALKS,positive
62304.0,"Benzinga’s Top Pre-Market Gainers (CELM, FEED, CXDC, CERS, ALKS)",2010-03-09 08:37:00-05:00,ALKS,positive
62305.0,AMLN Is Waiting For A Decision On Byetta,2010-03-08 20:08:00-05:00,ALKS,neutral
62306.0,"Alkermes, Inc. (ALKS) Third-Quarter Review",2010-02-05 15:12:00-05:00,ALKS,neutral
62307.0,Alkermes (ALKS) Raised to Buy On Consta's Record Sales ,2010-02-05 09:56:00-05:00,ALKS,neutral
62308.0,Volume Talks: Hot Stocks on Heavy Volume & Detailed Buy Write Option Trade,2009-11-18 09:01:00-05:00,ALKS,neutral
